摘要
目的分析奥西替尼联合紫杉醇^(+)顺铂(TP)化疗方案治疗晚期非小细胞肺癌(NSCLC)的价值。方法队列研究。抽取2021年2月至2024年2月安阳钢铁集团有限责任公司职工总医院收治的92例晚期NSCLC患者,按随机数字表法分为奥西替尼组和TP组,每组46例。TP组使用TP化疗方案,奥西替尼组在TP组的基础上使用奥西替尼。对比两组疗效、肿瘤标志物[癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)、血管内皮生长因子(VEGF)]水平、肿瘤体积、免疫功能(CD4^(+)、CD4^(+)/CD8^(+))及不良反应发生率。结果奥西替尼组总有效率(69.57%,32/46)高于TP组(47.83%,22/46),P<0.05。治疗后,奥西替尼组CEA、CYFRA21-1、VEGF水平低于TP组(P<0.05);治疗后,奥西替尼组肿瘤体积小于TP组(P<0.05);治疗后,奥西替尼组CD4^(+)、CD4^(+)/CD8^(+)水平高于TP组(P<0.05)。奥西替尼组不良反应发生率(6.52%,3/46)与TP组(15.22%,7/46)比较差异未见统计学意义(P>0.05)。结论奥西替尼联合TP化疗方案治疗晚期NSCLC的疗效显著,可以降低肿瘤标志物水平,缩小肿瘤体积,提高患者免疫功能,且具有安全性。
ObjectiveTo analyze the value of osimertinib combined with paclitaxel^(+)cisplatin(TP)chemotherapy regimen in the treatment of advanced non-small cell lung cancer(NSCLC).MethodsA total of 92 patients with advanced NSCLC treated in General Hospital of Staff and Workers of Anyang Iron and Steel Group Co.,Ltd.from February 2021 to February 2024 were selected for the cohort study.And they were divided into the osimertinib group and the TP group by random number table method,with 46 cases in each group.The TP group was treated with TP chemotherapy regimen,and the osimertinib group was treated with osimertinib based on the treatment of the TP group.The treatment efficacy,tumor markers levels including carcinoembryonic antigen(CEA),cytokeratin 19 fragment(CYFRA21-1)and vascular endothelial growth factor(VEGF),tumor volume,immune function evaluated by cluster of differentiation 4^(+)(CD4^(+))and CD4^(+)/cluster of differentiation 8^(+)(CD8^(+)),and incidence of adverse reactions were compared between the two groups.ResultsThe overall efficacy rate of the osimertinib group(69.57%,32/46)was higher than that of the TP group(47.83%,22/46),P<0.05.After treatment,the levels of CEA,CYFRA21-1 and VEGF in the osimertinib group were lower than those in the TP group(P<0.05).After treatment,the tumor volume in the osimertinib group was smaller than that in the TP group(P<0.05).After treatment,the levels of CD4^(+)and CD4^(+)/CD8^(+)in the osimertinib group were higher than those in the TP group(P<0.05).There was no significant difference in the incidence of adverse reactions between the osimertinib group(6.52%,3/46)and the TP group(15.22%,7/46),P>0.05.ConclusionsOsimertinib combined with TP chemotherapy regimen has significant efficacy in the treatment of advanced NSCLC,which can reduce levels of tumor markers,decrease tumor volume,and improve immune function,with great drug safety.
作者
姜媛利
Jiang Yuanli(Department of Tumor Hematology,General Hospital of Staff and Workers of Anyang Iron and Steel Group Co.,Ltd.,Anyang 455000,China)
出处
《中国实用医刊》
2025年第14期89-92,共4页
Chinese Journal of Practical Medicine
关键词
非小细胞肺癌
奥西替尼
肿瘤标志物
Carcinoma,non-small cell lung
Advanced stage
Osimertinib
Tumor markers
作者简介
姜媛利,Email:13513838603@163.com。
